Comparison of patients with mutant and wild-type HAVCR2
. | HAVCR2 mutated, n (%) . | HAVCR2 wild-type, n (%) . | P . |
---|---|---|---|
Number of patients | 13 | 40 | |
Median age, years | 34 (15-90) | 44 (1-71) | ns |
Sex, F/M | 10/3 | 31/9 | ns |
History of autoimmune disease | 3/11 (27) | 17/39 (44) | ns |
B symptoms | 11/12 (92) | 24/38 (63) | ns |
HPS | 4/13 (31) | 5/40 (13) | ns |
Severe HPS* | 3/13 (23) | 0/40 (0) | .02 |
Auto-antibodies | 5/8 (63) | 16/31 (52) | ns |
Polychemotherapy | 8/12 (67) | 5/39 (13) | .01 |
To achieve CR | 5/10 (50) | 3/31 (10) | .04 |
Immunosuppressors | 9/13 (69) | 33/40 (83) | ns |
To achieve CR | 5/10 (50) | 27/31 (87) | ns |
Stem cell transplant | 4/13 (31) | 1/40 (3) | .02 |
Autologous | 3/13 (23) | 1/40 (3) | ns |
Allogeneic | 1/13 (8) | 0/40 (0) | ns |
CR | 10/13 (77) | 31/40 (78) | ns |
Median CR duration (months) | 25.5 | 26.5 | ns |
Relapse | 3/12 (25) | 10/37 (27) | ns |
Deceased | 2/13 (15) | 2/39 (5) | ns |
From SPTCL | 0/2 | 1/2 | ns |
. | HAVCR2 mutated, n (%) . | HAVCR2 wild-type, n (%) . | P . |
---|---|---|---|
Number of patients | 13 | 40 | |
Median age, years | 34 (15-90) | 44 (1-71) | ns |
Sex, F/M | 10/3 | 31/9 | ns |
History of autoimmune disease | 3/11 (27) | 17/39 (44) | ns |
B symptoms | 11/12 (92) | 24/38 (63) | ns |
HPS | 4/13 (31) | 5/40 (13) | ns |
Severe HPS* | 3/13 (23) | 0/40 (0) | .02 |
Auto-antibodies | 5/8 (63) | 16/31 (52) | ns |
Polychemotherapy | 8/12 (67) | 5/39 (13) | .01 |
To achieve CR | 5/10 (50) | 3/31 (10) | .04 |
Immunosuppressors | 9/13 (69) | 33/40 (83) | ns |
To achieve CR | 5/10 (50) | 27/31 (87) | ns |
Stem cell transplant | 4/13 (31) | 1/40 (3) | .02 |
Autologous | 3/13 (23) | 1/40 (3) | ns |
Allogeneic | 1/13 (8) | 0/40 (0) | ns |
CR | 10/13 (77) | 31/40 (78) | ns |
Median CR duration (months) | 25.5 | 26.5 | ns |
Relapse | 3/12 (25) | 10/37 (27) | ns |
Deceased | 2/13 (15) | 2/39 (5) | ns |
From SPTCL | 0/2 | 1/2 | ns |
Bold indicates significant values.
F, female; M, male; ns, not significant; SPTCL, subcutaneous panniculitis-like T-cell lymphoma.